284 related articles for article (PubMed ID: 26317313)
1. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
[TBL] [Abstract][Full Text] [Related]
2. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
3. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
[No Abstract] [Full Text] [Related]
5. The Relationships between HER2 Overexpression and DCIS Characteristics.
Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
[TBL] [Abstract][Full Text] [Related]
6. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
[TBL] [Abstract][Full Text] [Related]
7. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
8. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
9. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
12. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
13. Gene amplification in ductal carcinoma in situ of the breast.
Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
[TBL] [Abstract][Full Text] [Related]
14. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
[TBL] [Abstract][Full Text] [Related]
15. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.
Oh YL; Choi JS; Song SY; Ko YH; Han BK; Nam SJ; Yang JH
Pathol Int; 2001 Feb; 51(2):94-9. PubMed ID: 11169147
[TBL] [Abstract][Full Text] [Related]
16. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
Barnes N; Haywood P; Flint P; Knox WF; Bundred NJ
Br J Cancer; 2006 Jan; 94(2):253-8. PubMed ID: 16421596
[TBL] [Abstract][Full Text] [Related]
17. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
19. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
20. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]